Caribou Biosciences/CRBU

$4.20

-3%
-
1D1W1MYTD1YMAX

About Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Ticker

CRBU

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Rachel Haurwitz

Employees

158

Headquarters

Berkeley, United States

CRBU Metrics

BasicAdvanced
$391.06M
Market cap
-
P/E ratio
-$1.45
EPS
-
Beta
-
Dividend rate
$391.06M
$8.59
$3.44
1.55M
11.972
-19,343.17%
-25.33%
-30.5%
-27.24%
11.343
1.04
1.062
148.91%
11.43%
40.76%

What the Analysts think about CRBU

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
376.19% upside
High $30.00
Low $10.00
$4.20
Current price
$20.00
Average price target

CRBU Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-985.71% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.5M
-85.17%
Net income
$-34.5M
245%
Profit margin
-985.71%
2,226.43%

CRBU Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 6.1%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.46
-$0.48
-$0.12
-$0.39
-
Expected
-$0.49
-$0.49
-$0.42
-$0.37
-$0.40
Surprise
-5.58%
-3%
-71.17%
6.1%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Caribou Biosciences stock?

Caribou Biosciences (CRBU) has a market cap of $391.06M as of April 13, 2024.

What is the P/E ratio for Caribou Biosciences stock?

The price to earnings (P/E) ratio for Caribou Biosciences (CRBU) stock is 0 as of April 13, 2024.

Does Caribou Biosciences stock pay dividends?

No, Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Caribou Biosciences dividend payment date?

Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders.

What is the beta indicator for Caribou Biosciences?

Caribou Biosciences (CRBU) does not currently have a Beta indicator.

What is the Caribou Biosciences stock price target?

The target price for Caribou Biosciences (CRBU) stock is $20, which is 376.19% above the current price of $4.2. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Caribou Biosciences stock

Buy or sell Caribou Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing